Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Запорізький Державний Медичний Університет, Юрій Геннадійович Самелюк, Андрій Григорович КаплаушенкоfiledCriticalЗапорізький Державний Медичний Університет
Priority to UAA201310452ApriorityCriticalpatent/UA108688C2/en
Publication of UA108688C2publicationCriticalpatent/UA108688C2/en
Agricultural Chemicals And Associated Chemicals
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The object of the invention: 2-(5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazol-3-ylthio) acetate acid as the antioxidant agents. Application area: pharmacy, medicine, veterinary medicine. Summary: 2-(5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazol-3-ylthio) acetate acid contains at N2-core of the atome of the 1,2,4-triazole amino group, in the 5-position of the 1,2,4-triazole nucleus it contains 3,4,5-trimethoxyphenyl radical, and also incorporates a divalent sulfur atom. Technical result: the ability to inhibit free radical oxidation processes, moderate solubility and storage stability, simple preparation procedure, reagents availability for synthesis.
UAA201310452A2013-08-272013-08-272-(5-(3,4,5-trimethoxyphenyl)-1h-1,2,4-triazol-3-ylthio) acetate acid as the antioxidant agents
UA108688C2
(en)
DERIVED FROM N2, N4-BIS (4- (PIPERAZIN-1-YL) PHENYL) PIRIMIDINE-2,4-DIAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE SUBSTANCE FOR PREVENTING OR TREATING CANCER
DERIVATIVES OF OXAZETIDINES, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT DERMATOLOGIC DISEASES FUNDAMENTALLY, AND THE RESPIRATORY, DIGESTIVE AND CARDIOVASCULAR, BETWEEN OTHER
Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide
Inhibitors of human myeloid leukemia based on 2-[2-(pyridine-2-ilmethylidene)hydrazine]-1,3-benzothiazole and 2-[2-(1-pyridine-2-ilethylidene)hydrazine]-1,3-benzothiazole dihydrate